

HSCT FOR HEMOGLOBINOPATHIES

Thalita Cristina de Mello Costa¹, Luiz Guilherme Darrigo Júnior², Ana Karine Vieira³, Cintia Delbem Albino⁴, George Maurício Navarro Barros⁵, Julia Lopes Garcia⁶, Laila Rigolin Fortunato⁷, Flavia Leite Souza Santos⁸, Gil Cunha De Santis⁹, Guilherme Fonseca¹⁰, Renato Luiz Guerino-Cunha¹¹, Belinda Pinto Simões¹²

1 Department of Medical Imaging, Hematology, and Clinical Oncology Ribeirão Preto Medical School - University of São Paulo (USP), Brazil - *2* Department of Pediatrics, Ribeirão Preto Medical School - University of São Paulo (USP), Brazil - *3* Clinical Hospital of UFMG - *4* Hospital de Base of São José do Rio Preto, Brazil; - *5* Department of Bone Marrow Transplantation and Cellular Therapy of Fundação Pio XII - Hospital de Câncer de Barretos, Brazil - *6* Department of Bone Marrow Transplantation, Israelita Albert Einstein Hospital; Itaci - Instituto da Criança – HCFMUSP, Brazil - *7* Bone Marrow Transplant Unit of Hospital da Criança e Maternidade of São José do Rio Preto, Brazil - *8* Cell-based Therapy and Regional Blood Center of Ribeirão Preto, Ribeirão Preto School of Medicine, University of São Paulo, Brazil - *9* Center for Cell-based Therapy and Regional Blood Center of Ribeirão Preto, Ribeirão Preto School of Medicine, University of São Paulo, Brazil - *10* Guilherme Fonseca, Department of Hematology, University of São Paulo, Brazil - *11* Renato Luiz Guerino-Cunha, Department of Medical Imaging, Hematology, and Clinical Oncology Ribeirão Preto Medical School - University of São Paulo (USP), Brazil - *12* Belinda Pinto Simões, Department of Medical Imaging, Hematology, and Clinical Oncology Ribeirão Preto Medical School - University of São Paulo (USP), Brazil

INTRODUCTION

Hemoglobinopathies are the most common monogenic diseases worldwide. There are approximately 300,000 to 400,000 newborns with hereditary hemoglobinopathies yearly. In Brazil it is estimated that there are around 70,000 – 100,000 people living with hemoglobinopathies, the most common being sickle cell disease. (Lobo et al., 2018) In Brazil the treatment of hemoglobinopathies in the public health system (Sistema Unico de Saude – SUS) is regulated by the Joint Ordinance No. 05 of February 19, 2018. The protocol established by this ordinance regarding sickle cell disease, includes newborn screening, antibiotic prophylaxis, hydroxyurea and monitoring of neurological disease with transcranial Doppler. In 2015 hematopoietic stem cell transplantation (HSCT), the only curative option for hemoglobinopathies currently available, was incorporated as a procedure reimbursed by SUS. Reimbursement for allogeneic

HSCT in thalassemia has been approved since 1999. In thalassemia, the main complications are due iron overload secondary to chronic blood transfusion. In sickle cell disease, the main complications arise from recurrent vaso-occlusive crises. Neurological events like seizures, stroke and silent ischemia and damage to several organs, reduces life expectancy by 20 years when compared to that of the normal population, according to a Brazilian study. (Lobo et al., 2018)

THALASSEMIA MAJOR

The greatest experience in HSCT for thalassemia is from the Pesaro group, which defined a risk stratification as early as 1994. The classification should be followed in patients under the age of 17 years (Lucarelli et al., 1998) and basically involves the quality of iron chelation and its consequences (Table I).

TABLE I - Pesaro Risk Classification

Risk factors	Class 1	Class 2	Class 3
Inadequate iron chelation	No	Yes/No	Yes
Hepatomegaly > 2 cm from RCM	No	Yes/No	Yes
Portal fibrosis	No	Yes/No	Yes

RCM, right costal margin

With this stratification thalassemia-free survival (TFS) was 90%, 80% and 65% for class 1, 2 and 3 patients, respectively. Transplant-related mortality (TRM), as expected, was also related to risk classification, being higher in class 3 patients. (Lucarelli et al., 1998)

RELATED HLA IDENTICAL DONORS (BONE MARROW OR CORD BLOOD)

Most of the data are from identical HLA related donors of Pesaro's group and two large retrospective analyses from the U.S. and Europe. The most used conditioning regimen in these studies, for patients under the age of 17 years and Pesaro classes 1 and 2, was myeloablative with Bussulfan (14 mg/kg), Cyclophosphamide (200 mg/kg) and anti-thymocyte globulin (ATG). (Lucarelli et al., 1998) In patients with Pesaro class 3, due to high transplant-related mortality (TRM) and graft failure it appears to be better to adopt a regimen with pre-HSCT immunosuppression with azathioprine, hydroxyurea, fludarabine and transfusion, with the objective of suppression of erythropoiesis, followed by reduced BuCy (cyclophosphamide of 120 mg/kg) (Sodani et al., 2004). With this new regimen, overall survival (OS) was 87% and thalassemia-free survival (TFS) was 82% in a group of 73 patients. (Gaziev et al., 2016) In patients over 16 years, this same regimen with pre-HSCT immunosuppression and reduced BuCY has been used. (Lucarelli et al., 2012)

The results with related HLA identical umbilical cord are similar to those of HLA identical bone marrow, both sources being currently recommended as standard of care for patients with transfusion-dependent thalassemia. (Locatelli et al., 2013)

Some groups have associated Thiotepa with classic BuCY to reduce the rejection rate, especially in children under the age of 4 years (Lucarelli et al., 2012). A recent study compared data on BuCYATG versus BuCYThio and found no differences even in children under 4 years. (Faulkner et al., 2017)

Unrelated HLA identical donors

Unrelated HSCT data in patients under 16 years and with HLA-identical donors (10/10) are similar to results with related HLA-identical donor. (La Nasa et al., 2005) It is important to reinforce that, for hemoglobinopathies, typing should include HLA DPB1, considering that incompatibilities in this locus are associated with inferior outcome. (Fleischhauer et al., 2006) (Ramprakash et al., 2017).

Data with unrelated umbilical cord blood, although restricted, resulted in high graft failure rates and,

consequently, reduction in overall survival. (Ruggeri et al., 2011) (Shah et al., 2015). For this reason, we do not recommend the use of unrelated umbilical cord blood.

HAPLOIDENTICAL DONORS

Two strategies have been employed: ex vivo lymphocyte depletion and in vivo depletion. Ex vivo depletion comprises CD34 selection or CD3+/CD19+ depletion. (Foell et al., 2017) With overall survival of 100%, the data are encouraging, despite slow immune recovery and frequent viral infections. (Oevermann et al., 2019)

Initial data on the use of post-transplant cyclophosphamide as T-cell depletion in vivo resulted in high rates of graft failure. Modifications such as increased TBI dose (200 cGy to 400 cGy) and inclusion of pre-conditioning immunosuppression, as that used in patients with Pesaro class 3, improved results significantly. (Bolaños-Meade et al., 2019). These transplants should be performed only in controlled clinical studies at this time.

SICKLE CELL DISEASE

Allogeneic Stem Cell Transplant indications

Currently, advances in conditioning regimens, graft-versus-host disease (GVHD) prophylaxis and better knowledge related to major complications of HSCT have made indications for HSCT broader, allowing both patients with severe disease and patients considered to be at higher risk for complications to be eligible for transplantation. (Stenger et al., 2019). However, the decision to perform HSCT should be considered within a scenario in which each case should be individualized, since the clinical evolution is usually very variable and the presence or absence of clinical symptoms in the first years of life does not predict how the patient will evolve in the future (Saraf & Rondelli, 2019).

Thus, young patients with symptomatic sickle cell disease who have a compatible HLA sibling donor should be referred for evaluation at a transplant center, preferably at preschool age. (Gluckman E. et al., 2017) In adults, the risks and complications of HSCT have gradually decreased, so that symptomatic patients with an identical HLA sibling donor can also benefit from an evaluation at a transplant center. (Stenger et al., 2019) Table 2 shows the main indications for HSCT for patients with sickle cell disease who are using hydroxyurea and/or chronic transfusion and present at least one of the conditions described below. We highlight that in the recommendations of this consensus there is no contraindication associated with the patient's age.

TABLE 2 - Indications for HSCT with HLA-identical sibling donors for sickle cell disease

Neurological alteration due to stroke, any neurological alteration persisting for more than 24 hours or altered imaging
Cerebrovascular disease associated with sickle cell disease
Two or more severe vaso-occlusive crises (including acute chest syndrome) in the last year
More than one episode of priapism
Presence of more than one antibody in patients on a hypertransfusion regimen
Osteonecrosis in more than one joint

PRE-TRANSPLANT CARE

Patients eligible for HSCT should be evaluated for their organ function and the presence of complications related to sickle cell disease (Table 3). (King et al., 2019) (Allen et al., 2018)

There is no contraindication for transplantation in patients with vascular alteration with Moyamoya's disease patten. Besides, we do not recommend pre-transplant surgical correction of this complication. In such cases, the decision to perform transplant shall be discussed and evaluated by the transplant center.

TABELA 3 - Pre-TCTH evaluation

Organ/System	Exams
Lung	Pulmonary function test (PFT)
Heart	Echocardiogram with tricuspid valve evaluation
Central Nervous System	Brain MRI Transcranial Doppler ultrasound (Up to 16 years) Neuropsychiatric evaluation if possible
Liver	Liver MRI T2* (according to the number of transfusions and serum ferritin)
Kidney	Glomerular filtration rate Urinalysis Microalbuminuria-creatinine ratio
Hematological system	Anti-HLA antibody test (mismatch) Extended erythrocyte phenotype Number of transfusions received Ferritin Keep HbS% < 30% before transplantation with simple transfusion or erythrocytapheresis
Multidisciplinary evaluation	Social worker Psychology Hemotherapy Endocrinology (discussion on risk of infertility) Gynecology-obstetrics (if considering fertility preservation) Pain team - anesthesia (if chronic pain) Psychiatry (if pre-existing psychiatric disease)

CONDITIONING REGIMENS

The conditioning regimen currently recommended for HSCT-candidates with an HLA-identical sibling donor is myeloablative (MAC). This regimen is based on the use of busulfan (Bu) 14-16 mg/kg (total dose) and cyclophosphamide (Cy) 200 mg/kg (total dose) with ATG. (Angelucci et al., 2014) Studies published using BuCy have demonstrated an OS in the pediatric population of 95 to 97%, and EFS of 85%. (Walters et al., 1996) (Panepinto et al., 2007) Bernaudin et al., 2020) It is important to highlight the role of the addition of ATG in conditioning regimens, since its inclusion decreases the incidence of GVHD, in addition to reducing the rejection rate from 22.6% to 3% in one study. (Bernaudin et al., 2020) Another recommended scheme is the use of fludarabine and busulfan, with results similar to those of BuCy. (Krishnamurti, L et al., 2019) There is a clear relationship between age at the moment of HSCT and the result obtained, which is superior in pediatric patients. (Cappelli et al., 2019) It is important to highlight that, despite the excellent results, myeloablative regimens are associated with higher morbidity and mortality due to the risk of infertility, secondary neoplasia, besides hindering transplantation in some cases in adults with important comorbidities and organic dysfunction. (Lukusa et al., 2009) The use of a less toxic myeloablative regimen with fludarabine (Flu), busulfan and ATG showed promising results with 95% EFS. (Bhatia et al., 2014)

HSCT with reduced intensity conditioning (RIC) or non-myeloablative (NMA) in the pediatric population resulted in high graft failure rate, thus not being recommended for this age group. (Iannone et al., 2003) In adults, conditioning containing alemtuzumab associated with low radiation dose (TBI 300 cGy) and sirolimus as prophylaxis for GVHD showed promising results. (Hsieh et al., 2014) However, the data are restricted, and we do not routinely recommend non-myeloablative regimens.

So, we recommend, for patients with a compatible sibling donor, myeloablative conditioning:

- A)** Cell source: Bone marrow or related umbilical cord
- B)** Busulfan 14 - 16 mg/kg IV + Fludarabine 150 mg/m² + rabbit ATG 4.5 – 7.5mg/kg
- C)** Busulfan 14-16 mg/kg IV + Cyclophosphamide 200 mg/kg + rabbit ATG 4,5 – 7,5 mg/kg
- D)** GVHD prophylaxis with cyclosporine and methotrexate. In the case of umbilical cord blood, methotrexate should be replaced by another immunosuppressive medication.

ALTERNATIVE DONORS

Although indications with alternative donors did not differ from indications with HLA-identical sibling donors, only the use of HLA-identical related umbilical cord blood showed results similar to those of bone marrow from HLA-identical siblings. (Locatelli et al., 2013) HSCT with matched unrelated donors are limited. A recent retrospective EBMT register study with 73 transplants showed that this is an important option for patients with severe complications (stroke) and non-responding to hydroxyurea. (Gluckman et al., 2020) The HSCT with haploidentical donors is an important option but with few cases published so far. (Foell 2018, de la Fuente 2019 , Oevermann 2019) Haploidentical transplants should be performed only in the context of clinical trials at this time. (Foell et al., 2017) (Oevermann et al., 2019) (Patel et al., 2020)

We emphasize that all patients (or their parents) diagnosed with sickle cell disease should receive information about all therapeutic options, including HSCT, as soon as possible. If they have siblings, they should be submitted to HLA typing. Patients with alterations indicating HSCT should be referred for evaluation as soon as possible at a transplant center.

TRANSFUSION SUPPORT

Patients with hemoglobinopathies usually arrive for transplant after a long period of exposure to red blood cell (RBC) transfusions. These patients have a higher rate of RBC alloimmunization than patients with cancer. Alloimmunization occurs in 10-20% of transfusion-dependent patients with thalassemia (Shas et al., 2015), while in patients with sickle cell disease, this rate varies between 20-50%. (Yazdanbakhsh et al., 2012) Planning transfusion must involve the hemotherapy service. The number of previous transfusions, the history of transfusion reactions, information about the presence of acquired anti-erythrocyte antibodies (AEA) and red cell phenotyping data are essential for a good HSCT planning.

The tests to be performed pre-HSCT are, in addition to ABO and Rh typing, the search for AEA, antibody titration, in case of ABO incompatibility between donor and recipient, direct antiglobulin test and extended RBC phenotyping. This must include at least the following antigens: C (RH2), E (RH3), c (RH4), and (RH5), K (KEL1), k (KEL2), Jka (JK1), Jkb (JK2), Fya (FY1), Fyb (FY2), S (MNS3), s (MNS4). Genotyping is recommended to elucidate complex cases and to identify RHCE variants, common in patients with sickle cell disease. (Allen et al., 2018) (Chou et al., 2020)

All patients with hemoglobinopathies undergoing HSCT should receive leukocyte reduced and irradiated cellular blood products. It is advisable to initiate irradiation in the pre-conditioning period. Washed blood products are indicated for patients with previous severe allergic / anaphylactic reactions and may be indicated in ABO-incompatible transplants to minimize the amount of antibodies infused. (De Santis et al., 2020)

CHIMERIS EVALUATION

The evaluation of chimerism in the context of HSCT in hemoglobinopathies is of fundamental importance. The recommendation is that the evaluation starts on the D+30 post-HSCT and repeated on D+60, D+90, D+120 (if no complete chimera D+90), D+150, D+180 and D+365 post-HSCT. In sickle cell disease, Bernaudin et al. showed that 44% of patients submitted to an HLA-identical donor HSCT maintained mixed chimera one year after HSCT. This fact, however, did not result in graft failure or disease manifestations. (Bernaudin et al., 2020) It is estimated that at least stable 25% donor mixed chimera is needed to prevent clinical manifestations of sickle cell disease. (Abraham et al., 2017) Chimerism analysis should ideally be performed in specific cell

populations (erythrocyte, myeloid and T cells) and not just in whole peripheral blood. (Abraham et al., 2017) Mixed chimerism data in donors that are not HLA-identical siblings are scarce and cannot be extrapolated safely to these other scenarios.

Approach to falling chimerism are not well established in the literature. Most authors recommend increasing immunosuppression, but no clear recommendation can be done.

IRON OVERLOAD

Patients with hemoglobinopathies usually present with iron overload for HSCT. We recommend, if possible, the best available iron chelation in the pre-HSCT period. (Hoffbrand et al., 2012) (Navneet S. Majhail et al., 2010) (Kontoghiorghes, 2020) There are no prospective data in literature so far, if a period of intense iron chelation pre HSCT will improve long term outcome, since iron overload is a long lasting process. Pre- and post-HSCT evaluation and approach of iron chelation are summarized in Table 5. Iron chelation options are: phlebotomy 6 mg/kg each 2 weeks; if well tolerated, it can be done weekly (AIII); deferoxamine 40 mg/kg IV ou SC 5/7 days of the week (AII); deferasirox 10 mg/kg/day (AII).

TABLE 5 - Recommendations regarding the evaluation and approach of iron overload.

	Iron overload evaluation	Toxicity evaluation of iron chelation
Before HSCT	Ferritin, Transferrin saturation Serum iron, MRI (LIC and T2*)	Kidney and hepatic function
6 months post-HSCT (from 6 months, if there is no GVHD or other complication that contraindicates it)	Ferritin Transferrin saturation MRI (T2* and LIC) (only if clinically indicated and in patients with pre-HSCT abnormalities)	Kidney and hepatic function every two weeks Most frequent assessments depending on clinical and laboratory assessment
12 months after the beginning of therapy and annually until normalization	Ferritin Transferrin saturation MRI (T2* and LIC)	

MRI, magnetic resonance imaging; LIC Liver iron concentration

LONG-TERM FOLLOW-UP

Long-term follow-up should be programmed according to the general recommendations for all HSCTs. However, some specific assessments, such as neurological, cardiac and hepatic, require special attention. (Dallas et al., 2013) (Majhail et al., 2012)

(Mishkin et al., 2020) (Bhatia, 2011) In relation to assessments of infections and immunizations, the recommendations of the corresponding chapters should be followed.

TABLE 6 - Long-term follow-up after HSCT for hemoglobinopathies

Evaluation and Exams	Days		Months				Years	
	100	120	6	9	12	18	2 years	Annual
Disease evaluation	X	X	X	X	X	X	X	X
Chimera evaluation (VNTR or STR, ABO group if incompatibility, karyotype, Hb electrophoresis)	X	X	X	X	X	X	X	X
General exams (hepatic and kidney function, biochemistry exams)	X	X	X	X	X	X	X	X
Brain MRI (for SCD)					X		X*	X*
Transcranial Doppler (for SCD if abnormalities in previous exams)					X		X*	X*
Neurological and cognitive evaluation (if available)	X				X		X*	X*
Cardiac and hepatic MRI (if abnormalities in previous exams)					X		X*	X*
TSH					X		X	X
Ferritin and transferrin saturation			X		X		X*	X*
Echocardiogram					X			
PFT			X	X	X	X	X	
Lipidogram			X		X		X	X
Bone mineral density					X			
Vaccination (according to institutional protocol)								
Fertility evaluation (≥11 years): FSH, LH, Testosterone and sperm analysis (for men)					X			
Skin, mouth, eyes, gynecological evaluation					X		X	X
Screening for malignancy					X		X	X
Growth and hormonal evaluation (≥ 11 years)					X		X	X

HSCT, hematopoietic stem cell transplantation; VNTR, variable number tandem repeat; ST, short tandem repeat; Hb, hemoglobin; MRI, magnetic resonance imaging; SCD, sickle cell disease; TSH, thyroid-stimulating hormone; PFT, pulmonary function tests; FSH, follicular-stimulating hormone; LH, lutenizing hormone

Recommendations

Transfusion-dependent thalassemia	Recommendation
HLA-identical donor (bone marrow or umbilical cord) Age <16 years Pesaro classes 1 and 2	Standard
Unrelated donor 10/10 (preferably bone marrow), Age < 16 years, Pesaro classes 1 and 2 HLA DPB1 without mismatch or with permissive mismatch	Standard
Unrelated cord blood	Not recommended
Haploidentical	Experimental protocol
Sickle cell disease	Recommendation
HLA-identical sibling donor (bone marrow or cord blood)	Standard
Unrelated umbilical cord blood	Not recommended (NR)
Haploidentical	Experimental protocol (EP)

REFERENCES

1. Abraham, A., Hsieh, M., Eapen, M., Fitzhugh, C., Carreras, J., Keesler, D., Guilcher, G., Kamani, N., Walters, M. C., Boelens, J. J., Tisdale, J., & Shenoy, S. (2017). Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. *Biology of Blood and Marrow Transplantation*; v. 23, n. 12, p. 2178-2183, 2017. <https://doi.org/10.1016/j.bbmt.2017.08.038>
2. Allen, E. S., Nelson, R. C., & Flegel, W. A. (2018). How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation. *Physiology & Behavior*; v. 176, n. 12, p. 139-148, 2017. <https://doi.org/10.1016/j.physbeh.2017.03.04>
3. Angelucci, E., Matthes-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M. D., et al. (2014). Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel. *Haematologica*; v. 99, n. 5, p.811-820, 2013. <https://doi.org/10.3324/haematol.2013.099747>
4. Bernaudin, F., Dalle, J. H., Bories, D., de Latour, R. P., Robin, M., Bertrand, Y., Pondarre, C., Vannier, J. P., Neven, B., Kuentz, M., Maury, S., Lutz, P., Paillard, C., Yakouben, K., Thuret, I., Galambrun, C., Dhedin, N., Jubert, C., Rohrlisch, P., ... Socié, G. (2020). Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. *Haematologica*; v. 105, n. 1. <https://doi.org/10.3324/haematol.2018.213207>
5. Bhatia, M., Jin, Z., Baker, C., Geyer, M. B., Radhakrishnan, K., Morris, E., Satwani, P., George, D., Garvin, J., Del Toro, G., Zuckerman, W., Lee, M. T., Licursi, M., Hawks, R., Smilow, E., Baxter-Lowe, L. A., Schwartz, J., & Cairo, M. S. (2014). Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. *Bone Marrow Transplantation*; v. 49, n.7, p. 913-920, 2014. <https://doi.org/10.1038/bmt.2014.84>
6. Bhatia, S. (2011). Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. *Expert Review of Hematology*; v.4, n. 4, p. <https://doi.org/10.1586/ehm.11.39>
7. Bolaños-Meade, J., Cooke, K. R., Gamper, C. J., Ali, S. A., Ambinder, R. F., Borrello, I. M., Fuchs, E. J., Gladstone, D. E., Gocke, C. B., Huff, C. A., Luznik, L., Swinnen, L. J., Symons, H. J., Terezakis, S. A., Wagner-Johnston, N., Jones, R. J., & Brodsky, R. A. (2019). Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. *The Lancet Haematology*; v.6, n.4, p. 183-193, 2019. [https://doi.org/10.1016/S2352-3026\(19\)30031-6](https://doi.org/10.1016/S2352-3026(19)30031-6)
8. Cappelli, B., Volt, F., Tozatto-Maio, K., Scigliuolo, G. M., Ferster, A., Dupont, S., Simões, B. P., Al-Seraihy, A., Aljurf, M. D., Almohareb, F., Belendez, C., Matthes, S., Dhedin, N., Pondarre, C., Dalle, J.-H., Bertrand, Y., Vannier, J. P., Kuentz, M., Lutz, P., ... Gluckman, E. (2019). Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. *Haematologica*; v.104, n.12. <https://doi.org/10.3324/haematol.2019.216788>
9. Chou, S. T., Alsawas, M., Fasano, R. M., Field, J. J., Hendrickson, J. E., Howard, J., Kameka, M., Kwiatkowski, J. L., Pirenne, F., Shi, P. A., Stowell, S. R., Thein, S. L., Westhoff, C. M., Wong, T. E., & Akl, E. A. (2020). American society of hematology 2020 guidelines for sickle cell disease: Transfusion support. *Blood Advances*; v.4, n.2, p. 327-355, 2019. <https://doi.org/10.1182/BLOODADVANCE.2019001143>
10. Dallas, M. H., Triplett, B., Shook, D. R., Hartford, C., Srinivasan, A., Laver, J., Ware, R., & Leung, W. (2013). Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. *Biology of Blood and Marrow Transplantation*; v.19, n. 5, p.820-830, 2013. <https://doi.org/10.1016/j.bbmt.2013.02.010>
11. De Santis, G. C., Costa, T. C. M., Santos, F. L. S., da Silva-Pinto, A. C., Stracieri, A. B. P. L., Pieroni, F., Darrigo-Júnior, L. G., de Faria, J. T. B., Grecco, C. E. S., de Moraes, D. A., Elias Dias, J. B., Oliveira, M. C., Covas, D. T., Cunha, R., & Simões, B. P. (2020). Blood transfusion support for sickle cell patients during hematopoietic stem cell transplantation: a single-institution experience. *British Journal of Haematology*. <https://doi.org/10.1111/bjh.16703>

12. Faulkner, L., Uderzo, C., Khalid, S., Marwah, P., Soni, R., Yaqub, N., Amanat, S., Fatima, I., Gilani, S. K., Zahra, T., Ramprakash, S., Gooneratne, L., Disanayake, R., Williams, S., Rathnayake, W., Srinivas, R., Sedai, A., Kumari, A., Parmar, L., ... Agarwal, R. K. (2017). ATG vs thiotepea with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. *Blood Advances*; v. 1. n.13, p. 792-801, 2017. <https://doi.org/10.1182/bloodadvances.2016004119>
13. Fleischhauer, K., Locatelli, F., Zecca, M., Orofino, M. G., Giardini, C., De Stefano, P., Pession, A., Iannone, A. M., Carcassi, C., Zino, E., & La Nasa, G. (2006). Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. *Blood*; v. 107, n. 7, p.2984-2992, 2006. <https://doi.org/10.1182/blood-2005-08-3374>
14. Foell, J., Pfirstinger, B., Rehe, K., Wolff, D., Holler, E., & Corbacioglu, S. (2017). Haploidentical stem cell transplantation with CD3 + /CD19 + - Depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: Results of a pilot study. *Bone Marrow Transplantation*; v.52, n.6, p. 938-940, 2017. <https://doi.org/10.1038/bmt.2017.49>
15. Gaziev, J., Isgrò, A., Sodani, P., Marziali, M., Paciaroni, K., Gallucci, C., De Angelis, G., Andreani, M., Testi, M., Alfieri, C., Ribersani, M., Galluccio, T., Battarra, M. R., Morrone, A., & Lucarelli, G. (2016). Optimal outcomes in young class 3 patients with thalassemia undergoing HLA-identical sibling bone marrow transplantation. *Transplantation*; v. 100, n.4, p. 925-932, 2016. <https://doi.org/10.1097/TP.0000000000000928>
16. Gluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Simões, B. P., Ferster, A., Dupont, S., De La Fuente, J., Dalle, J.-H., Zecca, M., Walters, M. C., Krishnamurti, L., Bhatia, M., Leung, K., Yanik, G., Kurtzberg, J., Dhedin, N., ... Chaudhury, S. (2017). Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. *Blood*; v. 129, n.11. <https://doi.org/10.1182/blood-2016-10-745711>
17. Gluckman, Eliane, Fuente, J. de la, Cappelli, B., Scigliuolo, G. M., Volt, F., Tozatto-Maio, K., Rocha, V., Tommaso, M., O'Boyle, F., Smiers, F., Cunha-Riehm, C. B. Da, Calore, E., Bonanomi, S., Graphakos, S., Paisiou, A., Albert, M. H., Ruggeri, A., Zecca, M., Lankester, A. C., & Corbacioglu, S. (2020). The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe. *Bone Marrow Transplantation*. <https://doi.org/10.1038/s41409-020-0847-z>
18. Hoffbrand, A. V., Taher, A., & Cappellini, M. D. (2012). How I treat transfusional iron overload. *Blood*; v. 120, n. 18, p.3657-3669, 2012. <https://doi.org/10.1182/blood-2012-05-370098>
19. Hsieh, M. M., Fitzhugh, C. D., Weitzel, R. P., Link, M. E., Coles, W. A., Zhao, X., Rodgers, G. P., Powell, J. D., & Tisdale, J. F. (2014). Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. *JAMA - Journal of the American Medical Association*; v. 312, n. 1, p. 48-56, 2014. <https://doi.org/10.1001/jama.2014.7192>
20. Iannone, R., Casella, J. F., Fuchs, E. J., Chen, A. R., Jones, R. J., Woolfrey, A., Amylon, M., Sullivan, K. M., Storb, R. F., & Walters, M. C. (2003). Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β -thalassemia. *Biology of Blood and Marrow Transplantation*; v.9, n.8, p.519-528, 2003. [https://doi.org/10.1016/S1083-8791\(03\)00192-7](https://doi.org/10.1016/S1083-8791(03)00192-7)
21. King, A. A., McKinstry, R. C., Wu, J., Eapen, M., Abel, R., Varughese, T., Kamani, N., & Shenoy, S. (2019). Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. *Biology of Blood and Marrow Transplantation*; v. 25, n.5, p. 174-178, 2019. <https://doi.org/10.1016/j.bbmt.2019.01.008>
22. Kontoghiorghe, G. J. (2020). How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation? *Expert Review of Hematology*; v. 13, n. 4. it. v 25, n. 5, p. 174-178, 2019. <https://doi.org/10.1080/17474086.2020.1719359>
23. Krishnamurti, Lakshmanan, Neuberg, D., Sullivan, K. M., Kamani, N., Abraham, A., Campigoto, F., Zhang, W., Dahdouh, T., De Castro, L. M., Parikj, S., Bakshi, N., Haight, A., Hassell, K. L., Loving, R., Wu, C. J., Wiedl, C., Waller, E. K., & Mark, C. (2019). Bone Marrow Transplantation for Adolescents and Young Adults with Sickle Cell Disease: Results of a Prospective Multicenter Pilot Study; v. 94, n. 4, p. 446-454, 2019. <https://doi.org/10.1002/ajh.25401>. Bone

24. La Nasa, G., Argioli, F., Giardini, C., Pession, A., Fagioli, F., Caocci, G., Vacca, A., De Stefano, P., Piras, E., Ledda, A., Piroddi, A., Littera, R., Nesci, S., & Locatelli, F. (2005). Unrelated bone marrow transplantation for β -thalassemia patients: The experience of the Italian bone marrow transplant group. *Annals of the New York Academy of Sciences*; v.1054, p. 186-195, 2005. <https://doi.org/10.1196/annals.1345.023>
25. Lobo, C. L. de C., Nascimento, E. M. do, Jesus, L. J. C. de, Freitas, T. G. de, Lugon, J. R., & Ballas, S. K. (2018). Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil. *Hematology, Transfusion and Cell Therapy*; v.40, n. 1, p. 37-42, 2018. <https://doi.org/10.1016/j.bjhh.2017.09.006>
26. Locatelli, F., Kabbara, N., Ruggeri, A., Ghavamzadeh, A., Roberts, I., Li, C. K., Bernaudin, F., Vermynen, C., Dalle, J. H., Stein, J., Wynn, R., Cordonnier, C., Pinto, F., Angelucci, E., Socié, G., Gluckman, E., Walters, M. C., & Rocha, V. (2013). Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. *Blood*; v. 122, n. 6, p. 1072-1078, p. 2013. <https://doi.org/10.1182/blood-2013-03-489112>
27. Lucarelli, G., Galimberti, M., Giardini, C., Polchi, P., Angelucci, E., Baronciani, D., Erer, B., & Gaziev, J. (1998). Bone Marrow Transplantation in Thalassemia The Experience of Pesaro. *Annals of the New York Academy of Sciences*; v. 850, p. 270-275, 1998. <https://doi.org/10.1111/j.1749-6632.1998.tb10483.x>
28. Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J. (2012). Hematopoietic stem cell transplantation in Thalassemia and Sickle Cell Anemia. *Cold Spring Harb Perspect Med*; v. 2, p. 1-11, 2012. <https://doi.org/10.1017/CBO9780511994876.043>
29. Lukusa, A. K., Vermynen, C., Vanabelle, B., Curaba, M., Brichard, B., Chantrain, C., Dupont, S., Ferrant, A., & Wyns, C. (2009). Bone marrow transplantation or hydroxyurea for sickle cell anemia: Long-term effects on semen variables and hormone profiles. *Pediatric Hematology and Oncology*, it. v. 26, n.4, p. 186-194, 2009. <https://doi.org/10.1080/07357900902892780>
30. Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, N., Davies, S., Okamoto, S., Seber, A., Socie, G., Szer, J., Van Lint, M. T., Wingard, J. R., & Tichelli, A. (2012). Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. *Bone Marrow Transplantation*; v. 47, n. 3, p. <https://doi.org/10.1038/bmt.2012.5>
31. Majhail, Navneet S., Lazarus, H. M., & Burns, L. J. (2010). A Prospective Study of Iron Overload Management in Allogeneic Hematopoietic Cell Transplantation Survivors. *Biology of Blood and Marrow Transplantation*; v. 16, n. 6, p. 832-837, 2010. <https://doi.org/10.1016/j.bbmt.2010.01.004>
32. Mishkin, A. D., Mapara, M. Y., Barhaghi, M., & Reshef, R. (2020). Fertility Concerns and Access to Care for Stem Cell Transplantation Candidates with Sickle Cell Disease. *Biology of Blood and Marrow Transplantation*; v. 26, n.8, p. 192-197, 2020. <https://doi.org/10.1016/j.bbmt.2020.03.025>
33. Oevermann, L., Schulte, J. H., Hundsdörfer, P., Hakimeh, D., Kogel, F., Lang, P., Corbacioglu, S., Eggert, A., & Sodani, P. (2019). HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches. *Bone Marrow Transplantation*; v. 54, p. 743-748, 2019. <https://doi.org/10.1038/s41409-019-0598-x>
34. Panepinto, J. A., Walters, M. C., Carreras, J., Marsh, J., Bredeson, C. N., Gale, R. P., Hale, G. A., Horan, J., Hows, J. M., Klein, J. P., Pasquini, R., Roberts, I., Sullivan, K., Eapen, M., & Ferster, A. (2007). Matched-related donor transplantation for sickle cell disease: Report from the Center for International Blood and Transplant Research. *British Journal of Haematology*; v. 137, n. 5, p. 479-485, 2007. <https://doi.org/10.1111/j.1365-2141.2007.06592.x>
35. Patel, D. A., Akinsete, A. M., de la Fuente, J., & Kassim, A. A. (2020). Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update. *Hematology/ Oncology and Stem Cell Therapy*, v. 13, n. 2, p. 91-97, 2020. <https://doi.org/10.1016/j.hemonc.2020.01.002>
36. Ramprakash, S., Agarwal, R. K., Dhanya, R., Sedai, A., Kumari, A., Parmar, L., Srinivas, R., Kakulamari, V. R., Marwah, P., Soni, R., Williams, S., Rathnayake, W., Sen, S., Tulpule, S., & Faulkner, L. (2017). Rejection of paternal vs maternal fully matched bone marrow grafts in children with thalassemia. *Bone Marrow Transplantation*; v. 52, n. 11, p. 1585-1586, 2017. <https://doi.org/10.1038/bmt.2017.199>

37. Ruggeri, A., Eapen, M., Scaravadou, A., Cairo, M. S., Bhatia, M., Kurtzberg, J., Wingard, J. R., Fath, A., Lo Nigro, L., Ayas, M., Purtill, D., Boudjedir, K., Chaves, W., Walters, M. C., Wagner, J., Gluckman, E., & Rocha, V. (2011). Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. *Biology of Blood and Marrow Transplantation*; v.17, n.9, p. 1375-1382, 2011. <https://doi.org/10.1016/j.bbmt.2011.01.012>
38. Saraf, S. L., & Rondelli, D. (2019). Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease. *Journal of Clinical Medicine*; v.8, n.10, p. <https://doi.org/10.3390/jcm8101565>
39. Shah, S. A., Shah, K. M., Patel, K. A., Anand, A. S., Talati, S. S., Panchal, H. P., Patel, A. A., Parikh, S. K., Parekh, B. B., Shukla, S. N., & Raut, S. S. (2015). Unrelated Umbilical Cord Blood Transplant for Children with β -Thalassemia Major. *Indian Journal of Hematology and Blood Transfusion*; v.31, n.1, p. 9-13, 2015. <https://doi.org/10.1007/s12288-014-0391-3>
40. Sodani, P., Gaziev, D., Polchi, P., Erer, B., Giardini, C., Angelucci, E., Baronciani, D., Andreani, M., Manna, M., Nesci, S., Lucarelli, B., Clift, R. A., & Lucarelli, G. (2004). A new approach for bone marrow transplantation in class 3 thalassemic patients aged less than 17 years. *Blood*; v. 104, n. 4, p. <https://doi.org/10.1182/blood-2003-08-2800>. Supported
41. Stenger, E. O., Shenoy, S., & Krishnamurti, L. (2019). How I treat sickle cell disease with hematopoietic cell transplantation. *Blood*; v. 134, n. 25, p. 2249- 2260, 2019. <https://doi.org/10.1182/blood.2019000821>
42. Walters, M. C., Patience, M., Leisenring, W., Eckman, J. R., Scott, J. P., Mentzer, W. C., Davies, S. C., Ohene-Frempong, K., Bernaudin, F., Matthews, D. C., Storb, R., & Sullivan, K. M. (1996). Bone marrow transplantation for sickle cell disease. *New England Journal of Medicine*; v. 335, n. 6. p. 369-376, 1996. <https://doi.org/10.1056/NEJM199608083350601>
43. Yazdanbakhsh, K., Ware, R. E., & Noizat-Pirenne, F. (2012). Red blood cell alloimmunization in sickle cell disease: Pathophysiology, risk factors, and transfusion management. *Blood*; v. 120, n. 3, p. 528-537, 2012. <https://doi.org/10.1182/blood-2011-11-327361>